Michael Petras: Yes. We think over the long range, Matthew, that we think this business will be high single digits, low double digits. If you remember, we talked about our company total gets about 3.5% to 5% price across the whole company, depending on the business. Nelson is typically on the lower end of that 3.5% to 4%. And then on top of that, you get volume mix, it gets you high single digits, low double digits. We still feel confident about the long-range projections of that business.
Matthew Mishan: And then when do you think you get back to that? And what’s holding it back at this point? It seems like some of your customers would be more normalized from a pushing product through like FDA at this point?
Michael Petras: Yes. We — as you know, throughout 2022, we had — if you kind of reflect on it, you had the PPE that was a very significant growth driver in ’21 and into ’22, which was very good mix, high margin in the volumes, and then we had to reallocate our staffing to accommodate the customer needs. As that kind of played out. We saw other testing slowing down in the validation area. We’ve started to see that rebound a little bit and move in the right direction. So I would say the validation volume has been the big one in the labor challenges that I think most labs are having challenges with. But I feel really good about what Joe and the team are doing there in the cost and price management. The service side, and it really shows with what our customers are telling us and the customer sat work.
So overall, directionally, it’s — and we’ve got some pockets that are doing really outstanding. So overall, I think it’s got a lot of momentum. And just the work that we’re doing with Sterigenics on validation coordination and helping improve customer turnaround times and really focusing on real assurance has been very helpful for both businesses.
Operator: Our next question will come from Luke Sergott with Barclays.
Luke Sergott: Just on the — a couple on the guide, can you give me a sense, did you guys include the 0% to 3% potential hit from the cobalt-60? Is that baked in your guide?
Michael Petras: No, it’s not.
Luke Sergott: Okay. All right. That’s fine. And then so on the Atlanta litigation on the personal injury. So when this starts, it’s fair to assume that this will be a longer duration on the proceedings and then especially given the different phases of the proof of causation. Just trying to get a sense of timing here with this one that starts in 2023? And then how the others kind of roll in through ’24?
Michael Petras: Yes. I would — Luke, the 1 case is 2023, October 2023 is the current schedule timing. The future cases are going to be an extended period of time as you referenced. Those are in a different county and there’ll be 2 different phases, as I mentioned, the first 1 is general causation and the second 1 is specific causation. So that’s going to take a little bit more time to play out.
Luke Sergott: Okay. So I mean like…
Michael Petras: I mean in ’24, ’25, I would think.